The could wait for BOT to achieve those numbers...
Intra-Cellular had 462 million sales in 23, and 680 million sales in 24, then was taken over under the assumption they would reach 5 billion in sales.
That is 76,000 sofdra patients - 12 scripts. For 462 million net sales, and 112,000 Sofdra patients 12 scripts.
Using net figure of 500 usd a script and March company reported on board rate of 2000 a month. BOT
Using worst case the March onboard rate but ignoring the onboard rate growth, BOT should be over 21,000 users by Dec. I'm expecting this to be higher though ( don't think we will stay at 2000 a month with additional sales force - makes no sense ). So could be net half the sales Intra-cellular had in 22/23 by Dec.
July reporting period will be very telling if onboard rate is exceeding 2000 and has continued to grow then forecasts will be wildly inaccurate, and will adjust. They get to 4000 a month, and we looking at annualised 300 mill net by Dec !
Absolutely massive potential. 1.3 million people currently using something... we just need 10% of them to be persuaded to try Sofdra and BOT is in the big leagues
BOT Price at posting:
44.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)